-
Corning Jerry CMO, CFO confirmed
Time of Update: 2021-04-19
Johannes Nippgen, the former head of Merck’s China R&D Center, as the Chief Medical Officer (CMO), and Mr.
It is understood that before joining Corning Jerry, Johannes Nippgen served as the head of the China R&D center at Merck Biopharmaceuticals.
-
None of the five global top 10 generic drug companies in India are from China!
Time of Update: 2021-04-19
Allergan's generic drug business acquired by Teva was renamed through continuous mergers and acquisitions by Watson Pharmaceuticals, the third largest generic drug company in the United States.
-
Recall of 4 batches of injections caused by solution crystallization
Time of Update: 2021-04-19
Injection produces crystalsInjection produces crystalsRecall announcementRecall announcementAfter receiving several complaints about injection crystallization, Zydus Pharmaceutical Company in the United States voluntarily recalled four batches of acyclovir sodium injection 50 mg/mL, with two packaging specifications of 10 mL and 20 mL.
-
Hengrui Medicine SHR8008 capsules and HRS2543 tablets were approved for clinical trials
Time of Update: 2021-04-19
After inquiries, at present, fluconazole, itraconazole, voriconazole and isaconazole and other similar products of SHR8008 have been approved for marketing at home and abroad.
Voriconazole was developed by Pfizer and was approved for marketing in the United States in 2002.
-
Eli Lilly's IL-2R agonist application clinical
Time of Update: 2021-04-19
Experimental results of non-human primate animal models show that Treg cells can be selectively expandedIn June 2020, Eli Lilly and Nektar jointly announced the phase Ib clinical study data of NKTR-358 for patients with moderate to severe systemic lupus erythematosus (SLE).
-
Takeda's treatment drug Feizeyou for acute hereditary angioedema episodes is approved to protect the lives of Chinese HAE patients
Time of Update: 2021-04-18
April 8, 2021, Shanghai — Takeda China announced that Feizeyou® (icatibant acetate injection) has been officially approved by the National Medical Products Administration for the treatment of heredity in adults, adolescents and children ≥2 years of age Acute onset of angioedema (HAE).
-
Xinjiang’s “2+4” Drug Purchasing Alliance Came to Promote Inter-provincial Centralized Procurement
Time of Update: 2021-04-18
The pace is accelerating, and another inter-provincial alliance brings a lot of purchases Xinjiang "2+4 " alliance is here On April 12, the Xinjiang Medical Insurance Bureau issued an announcement on publicly soliciting opinions and suggestions on the "2+4" Alliance of Xinjiang Production and Construction Corps of Xinjiang Uygur Autonomous Region to organize centralized drug procurement and use of drugs (draft for comments).
-
The first imitation of tens of billions of blockbuster varieties is declared for listing, and the market is fierce
Time of Update: 2021-04-18
. Medical Network News on April 13 Ten billion market, the first imitation is nearly Recently, CDE's official website showed that Simcere's application for the listing of Ibrutinib capsules was officially accepted by the State Food and Drug Administration, becoming the first generic drug of Ibrutinib submitted for marketing in China, and it is expected to realize the first imitation.
-
The market shrank by 48.3 billion!
Time of Update: 2021-04-18
Whether to enter or not to enter, pharmaceutical companies are suffering The state implements a mass procurement policy with the goal of ensuring the sales of bid-winning companies, reducing sales links, and guaranteeing corporate profits.
-
Why can't I buy the medicine that is "soul bargaining" in the medical insurance in the hospital?
Time of Update: 2021-04-18
Price reduction will not become the leading direction for drugs to enter the hospital's selection of drug catalogs Zhao Bin, deputy director of the Department of Pharmacy of Peking Union Medical College Hospital, said at the meeting that when drugs enter a hospital’s catalog, they must first meet clinical treatment needs.
-
The legal representative of a pharmaceutical company was investigated on suspicion of bribery
Time of Update: 2021-04-18
On April 10, the website of the State Supervision Commission of the Central Commission for Discipline Inspection found that Dai Longyong, the legal representative of Jiangxi Yongchang Pharmaceutical Co.
-
The state takes action! The medical insurance reform that benefits more than 300 million employees will usher in a big move
Time of Update: 2021-04-18
Medical Network, April 9 News On April 7, Chinese Premier Li Keqiang presided over an executive meeting of the State Council to determine measures to establish and improve the basic medical insurance outpatient mutual aid guarantee mechanism for employees, broaden the use of personal account funds, and reduce the medical burden of the masses.
-
Pfizer abrocitinib and Xeljanz review delayed by FDA for 3 months
Time of Update: 2021-04-18
In addition, the FDA has extended the review period of the supplementary new drug application (sNDA) for the oral anti-inflammatory drug Xeljanz/Xeljanz XR (tofacitinib, tofacitinib) for the treatment of adult patients with active ankylosing spondylitis (AS) by 3 months.
-
The price of 32 product regulations is lowered, Qilu, Chia Tai Tianqing, Eli Lilly and other well-known drugs are listed
Time of Update: 2021-04-18
On April 6, the Jiangsu Provincial Public Resources Trading Center issued a notice on adjusting the prices of some medicines.
The notice shows that the price of medicines for 32 product regulations has been lowered.
The specific price adjustments are as follows:
-
Junshi Biologics JS007 injection clinical trial application accepted
Time of Update: 2021-04-18
JS007 is a recombinant humanized anti-CTLA-4 monoclonal antibody injection independently developed by Junshi Biotechnology, which is mainly used for the treatment of advanced malignant tumors.
The anti-tumor effect of the drug, and was approved for the treatment of advanced melanoma.
-
Junshi PD-1 urothelial cancer indication is officially approved
Time of Update: 2021-04-18
The marketing application for this new indication is based on the POLARIS-03 study (NCT03113266), which is an open, single-arm, multi-center, phase II key registration clinical study, which aims to evaluate the failure of standard treatment of teriprizumab Safety and effectiveness in patients with locally advanced or metastatic bladder urothelial cancer.
-
Huahai will win the first blockbuster imitating the original research drug company to monopolize the market and break the situation
Time of Update: 2021-04-18
Figure 2: Sales of Topiramate Tablets Source: Mi Nei. com, China's public medical institutions terminal competition pattern According to data from Menet.
Figure 2: Sales of Topiramate Tablets Source: Mi Nei. com, China's public medical institutions terminal competition pattern According to data from Menet.
-
National Medical Insurance Administration: 24 billion prepaid funds guarantee free vaccination
Time of Update: 2021-04-18
On April 14, my country's new crown pneumonia vaccination was based on the principle of voluntary vaccinations by individuals and free of charge by the state. As of April 11, a total of 16,7343,000 d
-
Xi Hao, CFO of Cinda Bio: Accelerating innovation and evolution, striving to become a new force in the global pharmaceutical market
Time of Update: 2021-04-18
Three new drugs were launched, four products were commercialized, and PD-1 performance doubled; losses narrowed by more than 40%, and overseas presence deepened. . . With the disclosure of the 2020 f
-
Official support!
Time of Update: 2021-04-18
Online prescription drugs welcome breakthrough Hainan established the country's first independent construction and operation electronic prescription center The "Special Measures" proposes to support the development of Internet prescription drug sales.
